Chargement en cours...
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...
Enregistré dans:
| Publié dans: | Cancers (Basel) |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6827355/ https://ncbi.nlm.nih.gov/pubmed/31547040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101404 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|